FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2988332685> ?p ?o ?g. }

• W2988332685 endingPage "785" @default.
• W2988332685 startingPage "778" @default.
• W2988332685 abstract "To optimize strategies that mitigate the risk of graft loss associated with HLA incompatibility, we evaluated whether sequence defined HLA targets (eplets) that result in donor-specific antibodies are associated with transplant outcomes. To define this, we fit multivariable Cox proportional hazard models in a cohort of 118 382 United States first kidney transplant recipients to assess risk of death-censored graft failure by increments of ten antibody-verified eplet mismatches. To verify robustness of our findings, we conducted sensitivity analysis in this United States cohort and assessed the role of antibody-verified eplet mismatches as autonomous predictors of transplant glomerulopathy in an independent Canadian cohort. Antibody-verified eplet mismatches were found to be independent predictors of death-censored graft failure with hazard ratios of 1.231 [95% confidence interval 1.195, 1. 268], 1.268 [1.231, 1.305] and 1.411 [1.331, 1.495] for Class I (HLA-A, B, and C), -DRB1 and -DQB1 loci, respectively. To address linkage disequilibrium between HLA-DRB1 and -DQB1, we fit models in a subcohort without HLA-DQB1 eplet mismatches and found hazard ratios for death-censored graft failure of 1.384 [1.293, 1.480] for each additional antibody-verified HLA-DRB1 eplet mismatch. In a subcohort without HLA-DRB1 mismatches, the hazard ratio was 1.384 [1.072, 1.791] for each additional HLA-DQB1 mismatch. In the Canadian cohort, antibody-verified eplet mismatches were independent predictors of transplant glomerulopathy with hazard ratios of 5.511 [1.442, 21.080] for HLA-DRB1 and 3.640 [1.574, 8.416] for -DRB1/3/4/5. Thus, donor-recipient matching for specific HLA eplets appears to be a feasible and clinically justifiable strategy to mitigate risk of graft loss. To optimize strategies that mitigate the risk of graft loss associated with HLA incompatibility, we evaluated whether sequence defined HLA targets (eplets) that result in donor-specific antibodies are associated with transplant outcomes. To define this, we fit multivariable Cox proportional hazard models in a cohort of 118 382 United States first kidney transplant recipients to assess risk of death-censored graft failure by increments of ten antibody-verified eplet mismatches. To verify robustness of our findings, we conducted sensitivity analysis in this United States cohort and assessed the role of antibody-verified eplet mismatches as autonomous predictors of transplant glomerulopathy in an independent Canadian cohort. Antibody-verified eplet mismatches were found to be independent predictors of death-censored graft failure with hazard ratios of 1.231 [95% confidence interval 1.195, 1. 268], 1.268 [1.231, 1.305] and 1.411 [1.331, 1.495] for Class I (HLA-A, B, and C), -DRB1 and -DQB1 loci, respectively. To address linkage disequilibrium between HLA-DRB1 and -DQB1, we fit models in a subcohort without HLA-DQB1 eplet mismatches and found hazard ratios for death-censored graft failure of 1.384 [1.293, 1.480] for each additional antibody-verified HLA-DRB1 eplet mismatch. In a subcohort without HLA-DRB1 mismatches, the hazard ratio was 1.384 [1.072, 1.791] for each additional HLA-DQB1 mismatch. In the Canadian cohort, antibody-verified eplet mismatches were independent predictors of transplant glomerulopathy with hazard ratios of 5.511 [1.442, 21.080] for HLA-DRB1 and 3.640 [1.574, 8.416] for -DRB1/3/4/5. Thus, donor-recipient matching for specific HLA eplets appears to be a feasible and clinically justifiable strategy to mitigate risk of graft loss. Not all HLA epitope mismatches are equalKidney InternationalVol. 97Issue 4PreviewThe future of HLA matching in solid organ transplantation lies in epitope matching. The article by Sapir-Pichhadze et al. provides indirect evidence that there is a difference in immunogenicity between antibody-verified versus non-verified eplets. However, this difference was less clear for HLA class II, showing the need for additional efforts to identify truly immunogenic HLA class II epitope mismatches. Full-Text PDF In This IssueKidney InternationalVol. 97Issue 4PreviewAbumoawad et al. treated patients with atherosclerotic renovascular disease by infusing autologous, adipose-derived mesenchymal stem cells into the renal artery of kidneys with arterial stenosis. The procedure was well tolerated. Three months after infusion, renal blood flow increased significantly, and there was a modest increase in glomerular filtration rate. Tissue hypoxia declined, as did systolic blood pressure. Renal vein sampling from stem cell–treated kidneys showed a decline in endothelial growth factors and inflammatory cytokines. Full-Text PDF" @default.
• W2988332685 created "2019-11-22" @default.
• W2988332685 creator A5011580534 @default.
• W2988332685 creator A5035070955 @default.
• W2988332685 creator A5039567990 @default.
• W2988332685 creator A5046143675 @default.
• W2988332685 creator A5047886925 @default.
• W2988332685 creator A5048194032 @default.
• W2988332685 creator A5060990196 @default.
• W2988332685 creator A5061681954 @default.
• W2988332685 creator A5064535437 @default.
• W2988332685 creator A5069297637 @default.
• W2988332685 creator A5072604377 @default.
• W2988332685 creator A5084992978 @default.
• W2988332685 creator A5090312506 @default.
• W2988332685 date "2020-04-01" @default.
• W2988332685 modified "2023-09-25" @default.
• W2988332685 title "Epitopes as characterized by antibody-verified eplet mismatches determine risk of kidney transplant loss" @default.
• W2988332685 cites W1592875611 @default.
• W2988332685 cites W1669803836 @default.
• W2988332685 cites W1960048041 @default.
• W2988332685 cites W1969917104 @default.
• W2988332685 cites W1987055204 @default.
• W2988332685 cites W1997766738 @default.
• W2988332685 cites W1997944153 @default.
• W2988332685 cites W2001936053 @default.
• W2988332685 cites W2006527679 @default.
• W2988332685 cites W2032115368 @default.
• W2988332685 cites W2037918327 @default.
• W2988332685 cites W2040823354 @default.
• W2988332685 cites W2041019302 @default.
• W2988332685 cites W2094410733 @default.
• W2988332685 cites W2110604138 @default.
• W2988332685 cites W2127001878 @default.
• W2988332685 cites W2127841934 @default.
• W2988332685 cites W2160607034 @default.
• W2988332685 cites W2313390030 @default.
• W2988332685 cites W2555293543 @default.
• W2988332685 cites W2587929617 @default.
• W2988332685 cites W2624639385 @default.
• W2988332685 cites W2739465434 @default.
• W2988332685 cites W2756981671 @default.
• W2988332685 cites W2765221494 @default.
• W2988332685 cites W2774126255 @default.
• W2988332685 cites W2794831482 @default.
• W2988332685 cites W2796072301 @default.
• W2988332685 cites W2806018846 @default.
• W2988332685 cites W2808596977 @default.
• W2988332685 cites W2888192511 @default.
• W2988332685 cites W2948856749 @default.
• W2988332685 doi "https://doi.org/10.1016/j.kint.2019.10.028" @default.
• W2988332685 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32059998" @default.
• W2988332685 hasPublicationYear "2020" @default.
• W2988332685 type Work @default.
• W2988332685 sameAs 2988332685 @default.
• W2988332685 citedByCount "45" @default.
• W2988332685 countsByYear W29883326852020 @default.
• W2988332685 countsByYear W29883326852021 @default.
• W2988332685 countsByYear W29883326852022 @default.
• W2988332685 countsByYear W29883326852023 @default.
• W2988332685 crossrefType "journal-article" @default.
• W2988332685 hasAuthorship W2988332685A5011580534 @default.
• W2988332685 hasAuthorship W2988332685A5035070955 @default.
• W2988332685 hasAuthorship W2988332685A5039567990 @default.
• W2988332685 hasAuthorship W2988332685A5046143675 @default.
• W2988332685 hasAuthorship W2988332685A5047886925 @default.
• W2988332685 hasAuthorship W2988332685A5048194032 @default.
• W2988332685 hasAuthorship W2988332685A5060990196 @default.
• W2988332685 hasAuthorship W2988332685A5061681954 @default.
• W2988332685 hasAuthorship W2988332685A5064535437 @default.
• W2988332685 hasAuthorship W2988332685A5069297637 @default.
• W2988332685 hasAuthorship W2988332685A5072604377 @default.
• W2988332685 hasAuthorship W2988332685A5084992978 @default.
• W2988332685 hasAuthorship W2988332685A5090312506 @default.
• W2988332685 hasConcept C126322002 @default.
• W2988332685 hasConcept C147483822 @default.
• W2988332685 hasConcept C188280979 @default.
• W2988332685 hasConcept C203014093 @default.
• W2988332685 hasConcept C207103383 @default.
• W2988332685 hasConcept C2780303639 @default.
• W2988332685 hasConcept C2911091166 @default.
• W2988332685 hasConcept C44249647 @default.
• W2988332685 hasConcept C50382708 @default.
• W2988332685 hasConcept C71924100 @default.
• W2988332685 hasConcept C72563966 @default.
• W2988332685 hasConceptScore W2988332685C126322002 @default.
• W2988332685 hasConceptScore W2988332685C147483822 @default.
• W2988332685 hasConceptScore W2988332685C188280979 @default.
• W2988332685 hasConceptScore W2988332685C203014093 @default.
• W2988332685 hasConceptScore W2988332685C207103383 @default.
• W2988332685 hasConceptScore W2988332685C2780303639 @default.
• W2988332685 hasConceptScore W2988332685C2911091166 @default.
• W2988332685 hasConceptScore W2988332685C44249647 @default.
• W2988332685 hasConceptScore W2988332685C50382708 @default.
• W2988332685 hasConceptScore W2988332685C71924100 @default.
• W2988332685 hasConceptScore W2988332685C72563966 @default.
• W2988332685 hasFunder F4320310308 @default.
• W2988332685 hasFunder F4320311433 @default.

• next